Literature DB >> 17967299

Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.

Sydney M Evans1, Kevin L Du, Ara A Chalian, Rosemarie Mick, Paul J Zhang, Stephen M Hahn, Harry Quon, Robert Lustig, Gregory S Weinstein, Cameron J Koch.   

Abstract

PURPOSE: EF5, a 2-nitroimidazole hypoxia marker, was used to study the presence, levels, and prognostic significance of hypoxia in primary head and neck squamous cell tumors. METHODS AND MATERIALS: Twenty-two patients with newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, or larynx with at least 2 years of clinical follow-up were included in this study. Quantitative analyses of EF5 immunofluorescence was carried out, and these data were compared with patient outcome.
RESULTS: EF5 immunostaining showed substantial intra- and intertumoral hypoxic heterogeneity. The majority of cells in all tumors were well oxygenated. Three patterns of EF5 binding in cells were identified using criteria based on the cellular region that was stained (peripheral or central) and the relationship of binding to necrosis. We tested the association between EF5-binding levels with event-free and overall survival irrespective of the pattern of cellular binding or treatment regimen. Patients with tumors containing EF5-binding regions corresponding to severe hypoxia (< or =0.1% oxygen) had a shorter event-free survival time than patients with pO(2) values greater than 0.1% (p = 0.032). Nodal status was also predictive for outcome.
CONCLUSIONS: These data illustrate the potential utility of EF5 binding based on quantitative immunohistochemistry of tissue pO(2) and provide support for the development of noninvasive hypoxia positron emission tomographic studies with fluorine 18-labeled EF5.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967299      PMCID: PMC2737259          DOI: 10.1016/j.ijrobp.2007.04.067

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

1.  Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas.

Authors:  Ilse J Hoogsteen; Wenny J M Peeters; Henri A M Marres; Paul F J W Rijken; Franciscus J A van den Hoogen; Albert J van der Kogel; Johannes H A M Kaanders
Journal:  Radiother Oncol       Date:  2005-08       Impact factor: 6.280

2.  Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.

Authors:  Sydney M Evans; Amy E Schrlau; Ara A Chalian; Paul Zhang; Cameron J Koch
Journal:  J Invest Dermatol       Date:  2006-06-29       Impact factor: 8.551

3.  Hypoxia is important in the biology and aggression of human glial brain tumors.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

Review 4.  Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

Authors:  Dirk Vordermark; J Martin Brown
Journal:  Strahlenther Onkol       Date:  2003-12       Impact factor: 3.621

5.  Oxygenation predicts radiation response and survival in patients with cervix cancer.

Authors:  A W Fyles; M Milosevic; R Wong; M C Kavanagh; M Pintilie; A Sun; W Chapman; W Levin; L Manchul; T J Keane; R P Hill
Journal:  Radiother Oncol       Date:  1998-08       Impact factor: 6.280

Review 6.  Prognostic significance of tumor oxygenation in humans.

Authors:  Sydney M Evans; Cameron J Koch
Journal:  Cancer Lett       Date:  2003-05-30       Impact factor: 8.679

7.  Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Peter T Nelson; Ruth Collins; E Paul Wileyto; Kevin Jenkins; Stephen M Hahn; Craig W Stevens; Alexander R Judkins; Peter Phillips; Birgit Geoerger; Cameron J Koch
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

8.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

9.  Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin.

Authors:  Yoshihiro Azuma; Shu-Chuan Chou; Ruth A Lininger; Brian J Murphy; Mahesh A Varia; James A Raleigh
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

10.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

View more
  19 in total

1.  Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.

Authors:  Satish K Chitneni; Gerald T Bida; Michael R Zalutsky; Mark W Dewhirst
Journal:  J Nucl Med       Date:  2014-05-22       Impact factor: 10.057

2.  p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice.

Authors:  Chang-Lung Lee; Everett J Moding; Kyle C Cuneo; Yifan Li; Julie M Sullivan; Lan Mao; Iman Washington; Laura B Jeffords; Rafaela C Rodrigues; Yan Ma; Shiva Das; Christopher D Kontos; Yongbaek Kim; Howard A Rockman; David G Kirsch
Journal:  Sci Signal       Date:  2012-07-24       Impact factor: 8.192

3.  Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients.

Authors:  Noriyuki Fujima; Daisuke Yoshida; Tomohiro Sakashita; Akihiro Homma; Akiko Tsukahara; Yukie Shimizu; Khin Khin Tha; Kohsuke Kudo; Hiroki Shirato
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

Review 4.  Theory, instrumentation, and applications of electron paramagnetic resonance oximetry.

Authors:  Rizwan Ahmad; Periannan Kuppusamy
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI.

Authors:  Cameron J Koch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02       Impact factor: 9.236

6.  Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer.

Authors:  S K Sureshbabu; D Chaukar; S V Chiplunkar
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

7.  Usefulness of Pseudocontinuous Arterial Spin-Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period.

Authors:  N Fujima; D Yoshida; T Sakashita; A Homma; A Tsukahara; K K Tha; K Kudo; H Shirato
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

Review 8.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 9.  Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment.

Authors:  Carlos Ferrer Albiach; Antonio Conde Moreno; Marta Rodríguez Cordón; Virginia Morillo Macías; Ana Bouché Babiloni; Inmaculada Beato Tortajada; Angel Sánchez Iglesias; Alicia Francés Muñoz
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

Review 10.  Molecular aspects of tumour hypoxia.

Authors:  Saskia E Rademakers; Paul N Span; Johannes H A M Kaanders; Fred C G J Sweep; Albert J van der Kogel; Johan Bussink
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.